29 April 2017
News and Views
Links and Services
This week's issue of the New England Journal of Medicine evaluates ABT-450/r–ombitasvir and dasabuvir with ribavirin in previously untreated patients with HCV genotype 1 infection and no cirrhosis.
The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors